

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Announcement/2025-26

Date: 08.04.2025

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla complex
Bandra(E) Mumbai- 400051

Code No: 531146

Symbol: MEDICAMEQ

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Ma'am,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that:

Medicamen is pleased to announce signing of Distribution Agreement for following 3 products in European Market with XGX Pharma, Denmark.

Medicamen will hold the Marketing Authorization of these products. Two products out of three are of oncology and one product is Beta-lactam.

Oncology:

- ***Temozolamide capsules 250 mg***
- ***Bortozemib 3.5mg inj x1vial***

Beta-lactam:

- ***Amoxicillin, oral dispersible tablets 250 mg***

Kindly take the information on record.

Thanking You

Yours truly,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS: 44157